Detalimogene voraplasmid (detalimogene; formerly EG-70) demonstrated promising responses in patients with high-risk Bacillus ...

Gene anticipates filing a biologics licence application (BLA) for detalimogene voraplasmid to the FDA in H2 2026.

BOSTON & MONTREAL, November 11, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non ...

Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL:Lasme-cel in ...

Huawei submitted more than 10,000 technical contributions and published over 1,000 academic papers in the past year.

Holdings reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene ...

With its universal spectrum multiplier, Cohere Technologies is delivering value today while setting the stage for marquee 6G ...

R&D Pipeline -- IND-enabling activities for a PSMA-targeted ADC are on track for completion by year-end, further expanding the development portfolio.

Q3 2025 Earnings Call November 10, 2025 8:30 AM ESTCompany ParticipantsNicole RileyAmeet Mallik - CEO & DirectorMohamed ...

Q3 2025 Earnings Call Transcript November 10, 2025 ADC Therapeutics S.A. beats earnings expectations. Reported EPS is $-0.30023, expectations were $-0.4. Operator: Good morning, ladies and gentlemen, ...

Mahindra & Mahindra Ltd has made a regulatory filing to the stock exchange that it will form a 50:50 joint venture to ...

California, New York and Illinois were among the sanctuary states that the Department of Homeland Security singled out during ...